JNJ vs CRL
By Alex · Tickerpine
Johnson & Johnson vs Charles River Laboratories International, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | CRL |
|---|---|---|
| Price | $285.75 | $337.97 |
| Market cap | $687.89B | $16.19B |
| P/E ratio | 43.4 | 367.4 |
| ROE | 20.02% | 1.27% |
| Profit margin | 16.20% | 1.01% |
| Revenue growth | 5.90% | -2.20% |
| Dividend yield | 1.88% | 0.00% |
| Beta | 0.20 | 1.34 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs CRL in plain English
- JNJ is the bigger company — about 42.5× the market cap of CRL.
- JNJ is cheaper on earnings (P/E 43.4 vs 367.4).
- JNJ earns a higher return on equity (20% vs 1%).
- JNJ is growing revenue faster (6% vs -2%).
- JNJ pays a dividend (1.88%) while the other effectively doesn't.
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
CRL return calculator
See what $1,000 in Charles River Laboratories International, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.